Astec Lifesciences Limited (ASTEC) AI Stock Analysis

1 Followers

Astec Lifesciences Limited

(NSE:ASTEC)

Select Model

Rating:40Underperform

Price Target:INR 503.00▼(-9.12% Downside)

Action:downgraded

Date:11/11/26

The overall score is severely impacted by the company's unprofitability and significant cash burn, which raise liquidity concerns. The bearish technical picture, with the stock trading below all major moving averages and in oversold territory, further pressures the score. A modest improvement in the balance sheet's debt-to-equity ratio provides a slight offset but is insufficient to counter the dominant negative trends.

Positive Factors

Crop-protection business modelAstec operates across technical ingredients, intermediates and selected formulations used in insecticides, herbicides and fungicides. This positions the company within essential crop-protection supply chains and provides exposure to recurring agricultural demand across both domestic and international markets.

Negative Factors

Sustained operating lossesThe shift from solid profits to sizable operating and net losses across FY24–FY26 signals a material deterioration in earnings power. Continued negative profitability can weaken retained capital, reduce funding flexibility, and make the FY26 revenue recovery less durable unless margins improve.

Astec Lifesciences Limited (ASTEC) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 11.90B
Dividend Yield: ―
Average Volume (3M): 11.74K
Price to Earnings (P/E): -15.0
Beta (1Y): 1.09
Revenue Growth: 16.06%
EPS Growth: 36.97%
Country: India
Employees: 471
Sector: General
Sector Strength: 55
Industry: Agricultural Inputs

Astec Lifesciences Limited Business Overview & Revenue Model

Company Description

Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the co...

Astec Lifesciences Limited Financial Statement Overview

Summary

Financial performance is weak, driven by a net loss and deeply negative cash flows, though the balance sheet has improved with lower leverage. The Income Statement score of 25, Balance Sheet score of 35, and Cash Flow score of 15 reflect a company still burning cash and unprofitable, despite some top-line recovery.

Income Statement

25Negative

Balance Sheet

35Negative

Cash Flow

15Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	4.39B	4.48B	3.81B	4.58B	6.28B	6.77B
Gross Profit	686.74M	419.01M	-685.16M	1.33B	2.27B	2.86B
EBITDA	-46.13M	-15.49M	-662.07M	-2.69M	893.14M	1.65B
Net Income	-795.77M	-809.17M	-1.35B	-469.30M	255.65M	898.59M
Balance Sheet
Total Assets	7.94B	9.42B	8.81B	9.75B	9.79B	8.97B
Cash, Cash Equivalents and Short-Term Investments	22.82M	122.51M	8.55M	16.47M	27.54M	33.44M
Total Debt	3.31B	4.49B	5.55B	4.94B	3.41B	2.79B
Total Liabilities	4.59B	5.51B	6.46B	6.05B	5.60B	5.00B
Stockholders Equity	3.35B	3.91B	2.35B	3.69B	4.19B	3.96B
Cash Flow
Free Cash Flow	0	-1.18B	-302.20M	-1.25B	-426.03M	-803.74M
Operating Cash Flow	0	-1.13B	-83.99M	102.21M	746.56M	236.04M
Investing Cash Flow	0	-49.07M	-152.30M	-1.35B	-1.13B	-1.04B
Financing Cash Flow	0	1.27B	237.33M	1.25B	377.70M	804.77M

Astec Lifesciences Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price553.45

Price Trends

50DMA659.34Negative

100DMA659.10Negative

200DMA661.09Negative

Market Momentum

MACD-41.73Positive

RSI29.27Positive

STOCH22.81Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Negative. The current price of 553.45 is below the 20-day moving average (MA) of 614.61, below the 50-day MA of 659.34, and below the 200-day MA of 661.09, indicating a bearish trend. The MACD of -41.73 indicates Positive momentum. The RSI at 29.27 is Positive, neither overbought nor oversold. The STOCH value of 22.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTEC.

Astec Lifesciences Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:ASTEC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:BHARATRAS	74Outperform	INR 17.41B	7.61	―	0.05%	-5.17%	4.24%
IN:DHANUKA	73Outperform	INR 40.58B	14.53	―	0.22%	-0.06%	0.75%
IN:SHARDACROP	71Outperform	INR 64.62B	10.40	―	2.03%	17.28%	42.45%
IN:INSECTICID	66Neutral	INR 15.86B	12.44	―	0.91%	1.26%	-16.43%
IN:IPL	60Neutral	INR 13.94B	12.72	―	0.63%	2.89%	-9.47%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:ASTEC	40Underperform	INR 11.96B	-15.04	―	―	16.06%	36.97%

* General Sector Average

Performance Comparison

IN:ASTEC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:ASTEC	Astec Lifesciences Limited	553.45	-82.55	-12.98%
IN:BHARATRAS	Bharat Rasayan Limited	1054.00	-1506.31	-58.83%
IN:DHANUKA	Dhanuka Agritech Limited	903.45	-365.10	-28.78%
IN:INSECTICID	Insecticides (India) Limited	541.00	-128.01	-19.13%
IN:IPL	India Pesticides Ltd.	119.20	-59.68	-33.37%
IN:SHARDACROP	Sharda Cropchem Ltd.	728.15	-53.22	-6.81%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026

Astec Lifesciences Limited AI Stock Analysis